ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025
[Geniposide inhibits retinal cell apoptosis induced by glaucoma through the Hspa1a pathway].
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectivesGlaucoma is the leading cause of irreversible blindness worldwide. Reducing intraocular pressure is currently one of the most effective treatment strategies; however, it cannot completely prevent retinal ganglion cells (RGCs) death and the resulting vision loss. Traditional Chinese medicine has been widely investigated in glaucoma treatment. This study aims to determine whether geniposide can effectively inhibit retinal cell death and to explore its potential role in glaucoma therapy.
methodsCell experiments: Retinal R28 cells were divided into a control (CTL) group, an oxygen-glucose deprivation/reoxygenation (OGD/R) group, an OGD/R+geniposide (OGD/R+ Gen) group, and an OGD/R+Gen+heat shock protein family A member 1A (Hspa1a) small interfering RNA (OGD/R+Gen+H-KD) group. Proteomics analysis was first performed to identify key molecules altered after geniposide intervention. Quantitative real-time PCR (qPCR) and Western blotting were used to detect molecular changes after geniposide and H-KD interventions. Cell viability and death were assessed using cell counting kit-8 (CCK-8) and lactate dehydrogenase (LDH) assays. Flow cytometry, reactive oxygen species (ROS) detection, and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining were used to evaluate apoptosis. Animal experiments: SD rats were divided into a sham control (CTL) group, an acute high intraocular pressure (aHIOP) group, an aHIOP+Gen group, and an aHIOP+Gen+Hspa1a inhibitor apoptozole (aHIOP+Gen+Apo) group. Hematoxylin-eosin (HE) staining, TUNEL staining, and flash electroretinogram (fERG) were used to evaluate retinal structure, apoptosis, and functional changes.
results1) Proteomics combined with qPCR and Western blotting showed that Hspa1a expression was significantly increased after geniposide treatment. 2) Compared with the OGD/R group, the OGD/R+Gen group showed increased cell viability (
conclusionsGeniposide inhibits OGD/R- and aHIOP-induced retinal cell apoptosis and tissue injury through the Hspa1a-Akt pathway, providing a potential therapeutic target for glaucoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.